Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting

Swiss Medical Weekly

Volumn 131, Issue 21-22, 2001, Pages 303-310

  Gozzoli, V ^a   Palmer, A J ^a   Brandt, A ^a   Spinas, G A ^a  

^a NONE   (Switzerland)

Author keywords

Cost effectiveness; Diabetes mellitus; Screening; Secondary prevention

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLICATION; RISK FACTOR; SCREENING TEST; SIMULATION; SWITZERLAND;

EID: 0035795898     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
2. Diabetes care and research in Europe: The Saint Vincent declaration
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
5. The cost-effectiveness of different management strategies for type I diabetes: A Swiss perspective
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
7. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
8. Die St. Vincent-Deklaration: Eine umfrage zur diabetiker-betreuung in der schweiz
9. The JEVIN trial: A population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1989/1990
10. Cost effectiveness and evaluation of a structured therapy and education program for insulin-treated type II diabetic patients in Brandenburg
11. Diabetes intervention study. Multi-intervention trial in newly diagnosed NIDDM
12. Diabetes care management: A managed care approach
13. Staged diabetes management: Computerizing a disease state management program
14. A comprehensive register for diabetic outpatients: Experience with desktop computing from 1987-1996
15. Diabetes management: Shared care or shared neglect
16. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care
17. Impact of a diabetes electronic management system on the care of patients seen in a subspecialty diabetes clinic
18. An updated coronary risk profile. A statement for health professionals
19. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy
20. Probability of stroke: A risk profile from the Framingham study
21. Time preference
22. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
23. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine
24. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis
25. Effects of angiotensin-converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive non-insulin-dependent diabetic patients with microalbuminuria
26. Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study
27. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
28. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
29. Improved glucose regulation and microalbuminuria/proteinuria in diabetic patients treated with ACE inhibitors. A metaanalysis of published studies of 1985-1990
30. Effects of long-term enalapril treatment on persistent microalbumninuria in normotensive type 2 diabetic patients: Results of a 4-year, prospective, randomized study
31. Beneficial effect of alacepril, a new angiotensin-converting enzyme inhibitor on albuminuria and glycemic state: An open multicenter trial
32. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
33. Screening of diabetic patients for microalbuminuria in primary care - The PROSIT-project. Proteinuria screening and intervention
34. Resource utilization and costs of care in the Diabetes Control and Complications Trial